Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company TORRENT PHARMACEUTICALS LTD. 2 CIN NO. L24230GJ1972PLC002126 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2022-23, 2023-24, 2024-25 5 Incremental borrowing done in FY (T)(a) 1395.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 348.75 7 Actual borrowing done through debt securities in FY (T)(c) 500.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) NIL 8Quantum of (d), which has been met from (c)(e)* NA 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* NIL Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22, 2022-23, 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Chintan M TrivediDesignation :-Company Secretary Name of the Chief Financial Officer :- Sudhir Menon Designation : -Chief Financial Officer Date: 26/04/2023
26-04-2023
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyTORRENT PHARMACEUTICALS LTD. 2CIN NO.L24230GJ1972PLC002126 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 3368.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Chintan M Trivedi Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Sudhir Menon Designation: Chief Financial Officer EmailId: [email protected] Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-04-2023
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Redemption Of Non-Convertible Debentures

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Secured Redeemable Non-Convertible Debentures (NCDs) of Rs 145 crores (Rupees One Hundred Forty Five Crores) out of the total NCDs of Rs 195 crores (Rupees One Hundred Ninety Five Crores) issued under ISIN: INE685A07108 has been redeemed and repaid by the Company on 24-Apr-23.
24-04-2023
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Redemption Of Non-Convertible Debentures

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Secured Redeemable Non-Convertible Debentures (NCDs) of 200 crores (Rupees Two Hundred Crores) issued under ISIN: INE685A07116 has been fully redeemed and repaid by the Company on 21-Apr-23.
21-04-2023
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Compliance Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015

With reference to the above, we enclose herewith copy of the Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015 issued by RPAP & Co., Practicing Company Secretaries, Ahmedabad in respect of transfer of securities of the Company during the year ended on 31st March, 2023. Kindly find the same in order.
14-04-2023
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

In compliance with the requirements under 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Compliance Certificate for year ended on 31st March, 2023.
10-04-2023
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window

Pursuant to Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company (''Code'') and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the Company by Designated Persons stands closed from 1st April, 2023 and will be re-opened 48 hours after the submission of the Audited Financial Results for the Financial Year ended 31st March, 2023 to the Stock Exchanges.
30-03-2023

USFDA issues Form-483 with 1 observation to Torrent Pharma

USFDA conducted the pre-approval inspection of the Torrent Pharma Bileshwarpura-based plant from March 13-March 17.
17-03-2023
Next Page
Close

Let's Open Free Demat Account